Roberta Andreucci Pereira Gomes Gil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roberta Andreucci Pereira Gomes Gil has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Lidia Cheidde
Pontifical Catholic University of Sao Paulo
2 shared publications - Alexandre Negrão Pantaleão
Universidade Federal de Minas Gerais, Brasil
1 shared publication - Altair Pereira de Melo Neto
Federal University of Roraima , Boa Vista , Roraima, Brazil
1 shared publication - Arthur Tiemann Paião
Pontifical Catholic University of Sao Paulo
1 shared publication Bruna Gabriel Miranda
Federal University of Catalão
1 shared publication- Dillan Cunha Amaral
Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
1 shared publication
Latest Publications
- 24 July 2026
- Published by SAGE Publications in European Journal of Ophthalmology
Risk factors for graves’ orbitopathy: A systematic review and meta-analysis
Introduction: Understanding the modifiable risk factors for Graves’ orbitopathy (GO) is crucial for its prevention. Methods: We searched PubMed, Embase, and Web of Science databases following PRISMA guidelines. Studies reporting the presence of GO compared to patients with Graves’ disease (GD) without orbitopathy or healthy controls were included. Statistical analysis was performed using Review Manager 5.4.1. Results: Twenty-two studies met the inclusion criteria. Smoking increased the risk of GO, with odds ratios (ORs) of 2.00 (95% CI [1.47, 2.72]; p < 0.0001) for current smokers and 1.77 (95% CI [1.33, 2.37]; p = 0.0001) for former smokers, compared with GD patients without orbitopathy. Thyroidectomy was associated with a higher OR of Graves’ disease without orbitopathy, supporting a protective effect against orbitopathy (OR 2.53; 95% CI [1.03, 6.22]; p = 0.04). However, radioiodine therapy did not show a significant association (OR 0.89; 95% CI [0.42, 1.91]; p = 0.77). Biomarkers, including vitamin D ( p = 0.63), FT3 ( p = 0.89), FT4 ( p = 0.59), and TSH ( p = 0.40), showed no significant differences. In comparison to healthy controls, smoking remained a major risk factor for GO (OR 4.81; 95% CI [1.39, 16.70]; p = 0.01), while elevated FT4 (MD 8.87; 95% CI [1.64, 16.10]; p = 0.02) and decreased TSH (MD −1.23; 95% CI [-2.25, −0.20]; p = 0.02) levels were found in the GO groups. Conclusion: Our analysis provides a comprehensive understanding of clinical and biomarker-based risk factors to guide targeted prevention strategies.
- 24 July 2026
- Published by SAGE Publications in European Journal of Ophthalmology
Risk factors for graves’ orbitopathy: A systematic review and meta-analysis
Introduction: Understanding the modifiable risk factors for Graves’ orbitopathy (GO) is crucial for its prevention. Methods: We searched PubMed, Embase, and Web of Science databases following PRISMA guidelines. Studies reporting the presence of GO compared to patients with Graves’ disease (GD) without orbitopathy or healthy controls were included. Statistical analysis was performed using Review Manager 5.4.1. Results: Twenty-two studies met the inclusion criteria. Smoking increased the risk of GO, with odds ratios (ORs) of 2.00 (95% CI [1.47, 2.72]; p < 0.0001) for current smokers and 1.77 (95% CI [1.33, 2.37]; p = 0.0001) for former smokers, compared with GD patients without orbitopathy. Thyroidectomy was associated with a higher OR of Graves’ disease without orbitopathy, supporting a protective effect against orbitopathy (OR 2.53; 95% CI [1.03, 6.22]; p = 0.04). However, radioiodine therapy did not show a significant association (OR 0.89; 95% CI [0.42, 1.91]; p = 0.77). Biomarkers, including vitamin D ( p = 0.63), FT3 ( p = 0.89), FT4 ( p = 0.59), and TSH ( p = 0.40), showed no significant differences. In comparison to healthy controls, smoking remained a major risk factor for GO (OR 4.81; 95% CI [1.39, 16.70]; p = 0.01), while elevated FT4 (MD 8.87; 95% CI [1.64, 16.10]; p = 0.02) and decreased TSH (MD −1.23; 95% CI [-2.25, −0.20]; p = 0.02) levels were found in the GO groups. Conclusion: Our analysis provides a comprehensive understanding of clinical and biomarker-based risk factors to guide targeted prevention strategies.
- 23 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (7) , 3444-3455
Effect of Diabetes Mellitus on Clinical Outcomes After Transcatheter Aortic Valve Implantation: An Updated Systematic Review and Meta‐Analysis
Transcatheter Aortic Valve Implantation (TAVI) or Replacement (TARV) is a widely established treatment for symptomatic severe aortic stenosis (AS) in patients with high or intermediate surgical risk. Diabetes mellitus (DM) is prevalent in TAVR patients and is associated with an increased risk of cardiovascular events, which may elevate procedural risks. A systematic review and meta‐analysis were conducted following PRISMA guidelines. PubMed, Web of Science, and Cochrane databases were searched. A random‐effects model was applied, with 95% confidence intervals (CIs) and a 5% significance level. Statistical analyses were performed using RStudio version 4.4.1. Twelve studies with 214,444 patients were included, comprising 74,294 diabetic and 140,150 nondiabetic individuals. The analysis revealed no significant differences in all‐cause mortality, procedure mortality, 30‐day mortality, or complications such as bleeding, myocardial infarction, and major complications. However, 1‐year mortality was significantly higher in the diabetic group (RR: 1.51, 95% CI: 1.08–2.13). Diabetic patients were at higher risk for renal injury (RR: 1.46, 95% CI: 1.40–1.51) and lower risk of stroke (RR: 0.91, 95% CI: 0.83–0.99). The length of hospital stay and other major complications showed no significant differences. There was an increased risk of 1‐year mortality and renal injury in diabetic patients undergoing TAVI compared to non‐diabetics. Surprisingly, the risk for developing stroke in the diabetic group was significantly lower. In any case, the study emphasizes the need for tighter DM control to decrease the risk of such complications in the future.
- 23 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (7) , 3444-3455
Effect of Diabetes Mellitus on Clinical Outcomes After Transcatheter Aortic Valve Implantation: An Updated Systematic Review and Meta‐Analysis
Transcatheter Aortic Valve Implantation (TAVI) or Replacement (TARV) is a widely established treatment for symptomatic severe aortic stenosis (AS) in patients with high or intermediate surgical risk. Diabetes mellitus (DM) is prevalent in TAVR patients and is associated with an increased risk of cardiovascular events, which may elevate procedural risks. A systematic review and meta‐analysis were conducted following PRISMA guidelines. PubMed, Web of Science, and Cochrane databases were searched. A random‐effects model was applied, with 95% confidence intervals (CIs) and a 5% significance level. Statistical analyses were performed using RStudio version 4.4.1. Twelve studies with 214,444 patients were included, comprising 74,294 diabetic and 140,150 nondiabetic individuals. The analysis revealed no significant differences in all‐cause mortality, procedure mortality, 30‐day mortality, or complications such as bleeding, myocardial infarction, and major complications. However, 1‐year mortality was significantly higher in the diabetic group (RR: 1.51, 95% CI: 1.08–2.13). Diabetic patients were at higher risk for renal injury (RR: 1.46, 95% CI: 1.40–1.51) and lower risk of stroke (RR: 0.91, 95% CI: 0.83–0.99). The length of hospital stay and other major complications showed no significant differences. There was an increased risk of 1‐year mortality and renal injury in diabetic patients undergoing TAVI compared to non‐diabetics. Surprisingly, the risk for developing stroke in the diabetic group was significantly lower. In any case, the study emphasizes the need for tighter DM control to decrease the risk of such complications in the future.